Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Athira Pharma, Inc. (ATHA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates Completed end of Phase 2 meeting and continued engagement with U.S. Food and Drug Administration Appointed Andrew Gengos as Chief Financial Officer and Chief Business Officer Maintains strong balance sheet to support innovative clinical development pipeline in neurodegenerative diseases through key inflection points BOTHELL, Wash., August 10, 2023 — Athira Pharma, Inc. , a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended June 30, 2023, and provided pipeline and business updates. “During the second quarter, we advanced and strengthened our pipeline ..."
07/07/2023 SC 13G/A BlackRock Inc. reports a 1.8% stake in Athira Pharma, Inc.
06/09/2023 4 Gengos Andrew (See Below) has filed a Form 4 on Athira Pharma, Inc.
Txns: Bought 422 shares @ $3.3576, valued at $1.4k
Bought 2,859 shares @ $3.4, valued at $9.7k
Bought 11,719 shares @ $3.4395, valued at $40.3k
06/06/2023 4 Gengos Andrew (See Below) has filed a Form 4 on Athira Pharma, Inc.
Txns: Bought 10,012 shares @ $2.75, valued at $27.5k
Bought 6,582 shares @ $2.8598, valued at $18.8k
Bought 3,418 shares @ $2.945, valued at $10.1k
Bought 15,000 shares @ $3, valued at $45k
Bought 10,000 shares @ $2.9997, valued at $30k
Bought 10,000 shares @ $2.9999, valued at $30k
Bought 10,000 shares @ $3.0154, valued at $30.2k
06/06/2023 4 MOEBIUS HANS (Chief Medical Officer) has filed a Form 4 on Athira Pharma, Inc.
Txns: Granted 7,764 shares @ $2.41, valued at $18.7k
Exercised 7,882 options to buy @ $1.35, valued at $10.6k
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Athira Pharma Reports First Quarter 2023 Financial Results and Recent Pipeline and Business Updates Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer’s disease to focus on 40 mg dose Open label extension trial to be extended, providing up to 36 months of long-term exposure data ATH-1105 significantly prolongs survival and improves motor function in a mouse model of ALS; Strongly supports development as a treatment for ALS Strong balance sheet to support innovative clinical development pipeline in neurodegenerative diseases through key inflection points"
04/20/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
04/05/2023 ARS Form ARS - Annual Report to Security Holders:
04/05/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/05/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/31/2023 4 PICKERING GRANT (Director) has filed a Form 4 on Athira Pharma, Inc.
Txns: Bought 10,000 shares @ $2.33, valued at $23.3k
Bought 15,000 shares @ $2.47, valued at $37.1k
03/27/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/23/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/23/2023 8-K Quarterly results
Docs: "Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates On track to complete enrollment in Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer’s disease in mid-2023 with topline data in early 2024 Continuing to advance development of ATH-1105 as a potential clinical candidate for amyotrophic lateral sclerosis Strong balance sheet to support innovative clinical development pipeline in neurodegenerative diseases through key inflection points"
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/01/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/31/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/30/2023 SC 13G/A FRANKLIN RESOURCES INC reports a 0% stake in Athira Pharma, Inc.
01/23/2023 4 Worthington Mark (General Counsel) has filed a Form 4 on Athira Pharma, Inc.
Txns: Granted 150,000 options to buy @ $3.37, valued at $505.5k
01/23/2023 4 MOEBIUS HANS (Chief Medical Officer) has filed a Form 4 on Athira Pharma, Inc.
Txns: Granted 200,000 options to buy @ $3.37, valued at $674k
01/23/2023 4 MILESON GLENNA (CFO) has filed a Form 4 on Athira Pharma, Inc.
Txns: Granted 150,000 options to buy @ $3.37, valued at $505.5k
01/23/2023 4 Lenington Rachel (COO) has filed a Form 4 on Athira Pharma, Inc.
Txns: Granted 200,000 options to buy @ $3.37, valued at $674k
01/23/2023 4 CHURCH KEVIN (Executive VP, Research) has filed a Form 4 on Athira Pharma, Inc.
Txns: Granted 657 shares @ $2.74, valued at $1.8k
Granted 150,000 options to buy @ $3.37, valued at $505.5k
01/06/2023 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Financial Statements and Exhibits ...
Docs: "ATHIRA PHARMA, INC."
01/06/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
12/30/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/06/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/18/2022 8-K Quarterly results
11/17/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/10/2022 8-K Quarterly results
10/31/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy